Transforming Outcomes in AL Amyloidosis with Precision Medicine and Targeted Therapies

A team of expert oncologists delves into the latest developments in treating AL amyloidosis, placing particular emphasis on innovative therapies aimed at targeting amyloid deposits.

EP. 1: Exploring the Landscape Surrounding Light Chain Amyloidosis

December 15th 2023

Heather Landau, MD, initiates a discussion on the landscape of AL amyloidosis, offering insights into the definition and characteristics of this rare disease.

EP. 2: Expert Perspectives on Differentiating Signs and Symptoms in AL Amyloidosis Diagnosis

January 5th 2024

Vaishali Sanchorawala, MD, examines the signs and symptoms linked to AL amyloidosis, underscoring that distinctive symptoms may not manifest in patients until later stages of the disease, potentially causing delays in diagnosis.

EP. 3: Exploring Diagnostic Approaches for Patients with Light Chain Amyloidosis

January 5th 2024

A panel of oncology experts offer insights into the diagnosis of AL amyloidosis, emphasizing the difficulties associated with early detection.

EP. 4: Current Treatment Landscape for AL Amyloidosis

January 12th 2024

Jeffrey Zonder, MD, offers an overview of the current treatment landscape for AL amyloidosis.

EP. 5: Unmet Needs and Treatment Considerations in Managing AL Amyloidosis

January 12th 2024

A panel of expert oncologists examine current unmet needs in the treatment landscape for AL amyloidosis.

EP. 6: Treatment Strategies Using Monoclonal Antibodies in AL Amyloidosis

January 19th 2024

Jeffrey Zonder, MD, provides an overview of treatment strategies using monoclonal antibodies for the treatment of AL amyloidosis.

EP. 7: Optimizing Treatment Management Strategies in AL Amyloidosis with CD38-Directed mAbs

January 19th 2024

Faculty share insights into the treatment strategies using CD38-directed monoclonal antibodies (mAbs) in patients with AL amyloidosis.

EP. 8: Addressing Challenges in Managing AL Amyloidosis with Cardiac Involvement

January 26th 2024

Faculty delve into potential challenges related to the management of patients with AL amyloidosis and cardiac involvement, discussing the associated prognostic implications.

EP. 9: The Role of Cardiac Staging in Patients with AL Amyloidosis

January 26th 2024

A panel of expert oncologists discuss the importance of cardiac staging for patients with AL amyloidosis and its role in guiding overall treatment.

EP. 10: Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL

February 2nd 2024

A panel of expert oncologists explore novel therapies using monoclonal antibodies designed to target amyloid deposit, highlighting key data from the VITAL study.

EP. 11: AFFIRM-AL: Birtamimab in Patients with Mayo Stage IV AL Amyloidosis

February 2nd 2024

A panel of expert oncologists explore the ongoing AFFIRM-AL trial, examining birtamimab in patients with a diagnosis of Mayo stage IV AL amyloidosis.

EP. 12: Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials

February 9th 2024

Vaishali Sanchorawala, MD, provides insights on the pooled safety analysis of data from phase 1 to 3 trials, including PRONTO and VITAL, which investigated the use of birtamimab in patients with light chain (AL) amyloidosis.

EP. 13: The Potential Role of CAR T Therapy in AL Amyloidosis

February 9th 2024

A panel of expert oncologists discuss the underlying rationale and potential role for CAR T therapy in patients with AL amyloidosis.

EP. 14: NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis

February 16th 2024

Faculty offer insights on the NEXICART-1 phase 1 clinical trial investigating the safety and efficacy of NXC-201 in patients with AL amyloidosis and discuss potential clinical implications on the study’s findings.

EP. 15: Looking Ahead: Future Perspectives on AL Amyloidosis

February 16th 2024

Heather Landau, MD, invites panelists to provide their insights on the future outlook for the treatment of AL amyloidosis.